Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT06984822
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT06984822
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT06984822. Non-randomized; no masking; primary purpose prevention. Start 2025-08-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
- Acronym
- BiomarkerOCT
- Condition
- Diabetic Macular Edema
- Condition
- Visual Impairment
- Condition
- Diabetes Mellitus
- Condition
- Hyperglycaemia (Diabetic)
- Condition
- Oxidative Stress
- Condition
- Vascular Endothelial Growth Factor
- Condition
- VEGF
- Intervention (Drug)
- Anti-VEGF treatment
- Intervention (Device)
- Dexamethasone implant
- Intervention (Other)
- Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Lead sponsor
- Vastra Gotaland Region
Record details
- Record id
cardio:ct-nct06984822- Content hash
a63e3cd952556b365db4ae7b9997c9d47cde52bd27c0484b8c2e5052e6e74906